Report cards look positive, but some underachievers still spook investors
17 August 2015
Second quarter financial results for biotechnology companies are coming in thick and fast and overall, for the larger biotech companies at least, their report cards have been positive. However, a few companies failed to live up to expectations. As a result, the BioWorld Blue Chip Index, comprising 20 of the leading companies ranked by market cap, closed July with only a marginal 0.9 percent gain as the gainers just held sway over the decliners.
Feds come down in support of subsidizing copays in some clinical trials
17 August 2015
The feds recently said that device companies can subsidize copays in clinical trials, a move that was praised by food and drug attorneys at Hyman, Phelps & McNamara. An advisory opinion issued by the Office of Inspector General involved an incident in which subsidizing a copay was necessary in order to keep the trial's subjects blinded so that they would not know whether they were receiving the treatment or control procedure, known as a sham.
It is going to take a village to advance precision medicine
14 August 2015
Faced with more than 80 million genetic variants that may or may not affect a person's health or risk of disease, the FDA is realizing that it will take a village in the cloud to expand its current regulatory borders and deliver the promise of precision medicine.
Real-time data can put slow drug launches into the fast lane, researcher says
14 August 2015
Ask any pharma company: Drug launches are tough. A thousand things can go right or wrong. But that's where data--especially quickly gathered, targeted data--can make the difference.
Patent challenger Bass shrugs off Celgene's attack on his short-selling motives
14 August 2015
Money makes the world go round--the patent world, that is. That's the word from hedge funder Kyle Bass, who has been targeting drug patents he calls "low quality," and shorting pharma stocks along the way.
What does Google's corporate shuffle mean for its biotech ambitions?
14 August 2015
Google ($GOOG) is divvying up its composite parts, becoming, depending on whom you ask, the new Berkshire Hathaway, the next General Electric or something heretofore never seen. But the move could have mixed implications for Google's nascent but growing life sciences empire--including the high-profile, secretive biotech Calico --as shuffling things around could expose such moonshot projects to the pitchforks of profit-hungry investors.
Then and Now: How Prescription Drug Prices Fall Significantly Over Time
13 August 2015
Prescription drug prices fall significantly over time because the marketplace is unlike any other part of the U.S. health care system.
How slow can Big Pharma go in emerging markets?
13 August 2015
Industry watchers have pointed to a slowdown in pharma's emerging markets growth as a worrying sign for companies that have been heavily targeting developing nations while the U.S. and European markets stagnate. But just how slow has the growth become?
FDA makes its first approval of a 3-D printed drug
13 August 2015
For the first time, the FDA has approved a drug produced using a 3D printer. Aprecia Pharmaceuticals picked up the approval and distinction of being first past the post when the FDA gave the all-clear to its adjunctive therapy for the treatment of epilepsy.
The Future of Clinical Pathways
13 August 2015
Utilization of clinical pathways, in which an individual’s treatment follows a defined protocol, can help ensure patients receive the best possible care based on the most recent scientific data. However, clinical pathways can institutionalize a “cookie cutter” approach instead of personalized medicine, as well as limit treatment options in order to cut costs. So, which of these will be the future for clinical pathways?
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024